Introduction: MicroRNA-21 (miRNA-21) and lncRNA SNHG1 (small nucleolar RNA host gene 1) are known to be aberrantly upregulated and promote tumor progression in various cancers. Nevertheless, very few studies have determined the roles of tissue and circulating miRNA-21 and SNHG1 in ESCC patients. Particularly, knowledge about the characteristics of miRNA-21 and SNHG1 expression and their correlations with survival rates, as well as their interaction with each other remains inadequate in ESCC. Methods: Thse expression level of miRNA-21 and SNHG1 of tissues, serum and cell lines were detected by qRT-PCR, and the characteristics of their expression and clinicopathology were analyzed. Then, the diagnostic and prognosis value of serum and tissue miRNA-21 and SNHG1 were evaluated, respectively. In addition, the interaction with each other between miRNA-21 and SNHG1, as well as the effect on ESCC cell proliferation were further clarified. Results: The expression level of miRNA-21 and SNHG1 are significantly upregulated in tissues, serum and cell lines of ESCC, and tissue miRNA-21 and SNHG1 significantly correlates with lymph node metastasis, TNM stage, tumor size, and poor overall survival in ESCC patients. The receiver operating characteristic (ROC) curves show that areas under the ROC curve (AUC) for serum miRNA-21 and SNHG1 are 0.928 and 0.850, respectively. Pearson correlation coefficient indicated that the expression levels of miRNA-21 and SNHG1 in frozen cancerous tissues are significantly associated with their respective serum levels. Further, Cox univariate and multivariate analyses reveal that miRNA-21 and SNHG1 are independent prognostic factors for overall survival (OS) and disease-free survival (DFS) in ESCC patients. In addition, our in vitro data revealed a novel regulatory pathway, in which miRNA-21 is probably a unidirectional upstream positive regulator of SNHG1 in ESCC cells, and the interaction between miRNA-21 and SNHG1 plays an important role in the proliferation of ESCC cells. Discussion: In summary, our data show that SNHG1 may be a novel downstream target of miRNA-21 and not vice versa in ESCC cells and contributes significantly toward the proliferation of ESCC cells. These findings suggest that miRNA-21 and SNHG1 may serve as potential diagnostic, prognostic biomarkers and therapeutic targets for ESCC patients.
Introduction
Esophageal cancer (EC) is the seventh most common cancer in the world and the sixth leading cause of cancer-related deaths. 1 Esophageal squamous cell carcinoma (ESCC) is the major histopathological form accounting for over 90% of ECs, which is also the most frequent type of histopathology in China. 2 ESCC has been reported to be abnormally frequent in Xinjiang, the northwestern part of China than other regions. 3 Despite some recent advances in the exploration of its likely etiological mechanisms that include behaviors and environmental risk factors as well as gene alterations, 4 the complicated mechanisms are still largely unknown; leading to a 5-year survival rate of about 10-20%. 1, 5 Therefore, a better understanding of the molecular mechanisms underlying ESCC pathogenesis and progression will substantially aid in improving the diagnosis, prognosis, and treatment of ESCC. MicroRNAs (miRNAs) are a class of single-strand noncoding RNAs consisting of 18~24 nucleotides, which are thought to function through the inhibition of effective mRNA translation of target genes. 6, 7 An increasing number of studies have shown that various specific miRNA expression profiles are related to the development of different types of cancer implying that miRNAs can function as tumor suppressors or oncogenes. 8 MicroRNA-21 (miRNA-21), an oncogenic miRNA, is encoded by the MIR21 gene located on chromosome 17q23.2. 9 Increased miRNA-21 expression during carcinogenesis and in tumor samples indicates that it functions to promote cell proliferation and migration and to inhibit cell apoptosis in majority of cancers, such as liver cancer, 10 breast cancer, 11 non-small cell lung cancer, 12 and ESCC. 13 Additionally, miRNA-21 is associated with poor prognosis as well as with reduced chemosensitivity of cancer cells to anticancer agents in ESCC. 14 In terms of downregulation of proteins, miRNA-21 has been reported to specifically target tumor suppressors such as PTEN, 15 Bcl-2, 15 Smad7, 16 and PDCD4. 17 Long non-coding RNAs (lncRNAs) play crucial roles in many diseases via controlling gene expression. 18 One of their mechanisms of action involves the formation of regulatory networks with other RNA species, such as miRNAs and mRNAs. 19 It has been well established that miRNAs can interact with lncRNAs to participate in human diseases, such as different types of cancers. 20 LncRNA SNHG1
(small nucleolar RNA host gene 1), located at chromosome 11q12.3, is expressed in the nucleus of most cells as well as in the cytoplasm in certain cell-types. 21 SNHG1 is widely distributed in the body and participates in regulating proliferation, invasion, and metastasis, as well as acts as an indicator of poor survival in many types of cancer including non-small cell lung cancer, 22 hepatocellular carcinoma, 23 and colorectal cancer. 24 More recent studies suggest that the tumor-associated miRNAs and lncRNAs may possess the potential to be explored as sensitive and specific cancer biomarkers for diagnostic, prognostic, or monitoring of cancers. 20 However, no reports have yet determined the roles of tissue and circulating miRNA-21 and SNHG1 in ESCC patients. Particularly, the nature of miRNA-21 and SNHG1 expression levels and its correlation with survival rates, as well as the regulatory effect between miRNA-21 and SNHG1 still remains unexplored in ESCC. These facts thus prompted us to explore the role of miRNA-21 and SNHG1 in ESCC.
In the present study, we found that tissue miRNA-21 and SNHG1 are significantly upregulated and correlated with lymph node metastasis, TNM stage, and tumor size; and may serve as independent predictors for the survival of ESCC patients. Serum miRNA-21 and SNHG1 may serve as potential diagnostic indexes. Further, the study revealed the existence of a unidirectional regulatory interaction between miRNA-21 and SNHG1 in addition to the role of miRNA-21 overexpression in promoting ESCC cells proliferation through upregulation of SNHG1.
Materials and Methods

Tissues and Serum Specimens
60 serum ESCC samples, and 42 paired ESCC tissues and adjacent non-cancerous tissues were obtained from ESCC patients who underwent resection of the ESCC from February 2012 to December 2012 at the Affiliated Tumor Hospital of Xinjiang Medical University (Urumqi, Xinjiang, China). Tissue samples were collected from patients who provided serum samples. 6 healthy tissues (benign mass tissues with negative biopsy being from the esophageal region collected by gastroscopy) and 60 healthy serum samples came from volunteers. All tissue samples were came from untreated by chemotherapy or radiotherapy patients undergoing surgery and were snap frozen in liquid nitrogen and stored at −80°C until the extraction of RNA. The diagnosis of all tissues specimens was verified by histopathological examination. For all the samples, data on patient gender, age, tumor size, location, smoking, differentiation, vessels invasion, nerve invasion, lymph node metastatic, and TNM stage were collected. Tumor stages were assessed according to the Seventh Edition of the Cancer Staging Manual of the American Joint Committee on Cancer. The use of these tissues specimens was conducted in accordance with protocols approved by the Review Board of the Affiliated Tumor 
Results
miRNA-21 and SNHG1 are Up-Regulated in Tumor Tissues of ESCC Patients
To investigate the clinical significance of miRNA-21 and SNHG1 in ESCC, we measured miRNA-21 and SNHG1 expression using qRT-PCR assays in 42 paired ESCC tissues and adjacent non-cancerous tissues (ANCTs) prior to chemotherapy. The results indicated that miRNA-21 is significantly overexpressed in 30 ESCC tissues, with twice the expression in 24 ESCC tissues compared with ANCTs (P<0.0001) ( Figure 1A ). Analogously, SNHG1 is also significantly overexpressed in 29 ESCC tissues with two times greater expression in 20 ESCC tissues than in ANCTs (P<0.0001) ( Figure 1C ). In addition, compared with healthy controls and ANCTs group, the levels of miRNA-21 and SNHG1 are significantly upregulated in patients with ESCC, while there is also a slight increase in the distribution of miRNA-21 and SNHG1 in the ANCTs group compared with that in the healthy control group (P<0.0001) ( Figure 1B and D).
miRNA-21 and SNHG1 Levels Correlate with Clinicopathologic Characteristics of ESCC Patients
Next, the correlations between expression levels of miRNA-21 and SNHG1 and clinicopathologic characteristics were analyzed by χ 2 or Fisher test. In this study, miRNA-21 and SNHG1 expression levels of ESCC tissue over 2-fold compared with ANCTs were considered to indicate high expression levels. The results indicated that upregulated miRNA-21 expression significantly correlates with TNM stage (P=0.010) and lymph node metastasis (P=0.008); and upregulated SNHG1 expression correlates with lymph node metastasis (P=0.016) and tumor size (P<0.0001) with nonexistent significant links to other clinicopathological features such as age, gender, smoking, location, differentiation, nerve invasion, and invasion of vessels (P>0.050) ( Table 1) . Further analysis revealed that the expression level of miRNA-21 is markedly increased in the patients positive for lymph node metastasis compared with lymph node metastasis negative patients (P<0.0001) (Figure 2A ), and also highly correlated with TNM staging (Ⅰ vs Ⅱ P=0.008; Ⅱ vs Ⅲ P=0.026; Ⅰ vs Ⅲ P<0.0001) Figure 3B and E). Additionally, the receiver operating characteristic (ROC) curve showed that area under the ROC curve (AUC) of serum miRNA-21 is 0.928, and the sensitivity and specificity of serum miRNA-21 are 88.3% and 97.3%, respectively ( Figure 3C ). The AUC of serum SNHG1 is 0.850, and the sensitivity and specificity of serum SNHG1 are 77.4% and 92.5%, respectively ( Figure 3F ). These data suggest that serum levels of miRNA-21 and SNHG1 may serve as promising diagnostic biomarkers for ESCC patients. Figure 5A and B). These data suggest that miRNA-21 and SNHG1 are positively highly expressed in ESCC patients.
miRNA-21 Is a Unidirectional Upstream Regulator of SNHG1
In order to clarify the relationship of miRNA-21 and SNHG1 in ESCC cells, we analyzed the expression levels of miRNA-21 and SNHG1 and how they affect each other. According to miRNA-21 and SNHG1 expression levels in different esophageal cell lines, qRT-PCR showed that miRNA-21 and SNHG1 are highly expressed in ESCC cell lines TE-1, Eca-109, KYSE-170, and KYSE-150 compared with HET-1; with Eca-109 and KYSE-150 exhibiting respectively the highest and lowest expression of miRNA-21 and SNHG1 among these 4 ESCC cell lines ( Figure 6A Figure 6D and E). However, no significant changes in expression levels of miRNA-21 were found in these cells after either overexpressing or downregulating SNHG1 ( Figure 6F and G). Thus, our data clearly suggests that miRNA-21 may be most likely an upstream unidirectional positive regulator of SNHG1 in ESCC cells.
miRNA-21 Promotes ESCC Cell Proliferation Through SNHG1
Correlation of SNHG1 expression with tumor size, as already shown, indicates the involvement of SNHG1 in tumor growth. In order to validate this hypothesis, proliferation abilities of ESCC cells of each group were assessed by the CCK-8 assay. It was found that compared with C and NC groups, miRNA-21 and SNHG1 overexpression promoted the proliferation of both Eca-109 and KYSE150 ESCC cells (P<0.01). On the other hand, SNHG1 siRNA silencing played an opposite role in ESCC cell proliferation (P<0.01). In addition, miRNA-21 overexpression partially reversed the inhibitory effects of SNHG1 downregulation on cancer cell proliferation (P<0.05) ( Figure 7A and B) . Interestingly, the clone formation assay also further confirmed the effect of miRNA-21 and SNHG1 on the proliferation of Eca-109 and KYSE150 cells ( Figure 7C ). Therefore, it can be inferred that miRNA-21 plays an important role in promoting ESCC cell proliferation possibly through SNHG1.
Discussion
Many miRNAs and lncRNAs are expressed in a highly tissue-specific manner and contribute to the establishment and maintenance of the characteristic tissue-related gene expression. It is well-known that the cross-talk between miRNAs and lncRNAs participates in many cellular biological processes. miRNA-21 is one of the prominent miRNAs implicated in the oncogenesis and progression of various human cancers. Not only has it been implicated in the promotion of tumor growth, anti-apoptosis, and proliferation, but it has also been shown to be associated with resistance toward radiosensitivity or/and chemotherapy.
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SNHG1 is one of the most significant regulatory lncRNAs in human cancers, and it has been highlighted as a potential candidate for diagnostic, prognostic, and therapeutic purposes in malignancies. 26 Previously, several reports have demonstrated that miRNA-21 and SNHG1 expression plays a crucial role in the proliferation of ESCC cells by serving as accelerators of malignancy, and downregulation of miRNA-21 or SNHG1 inhibits the proliferation and invasion of ESCC cells. 27, 28 Various studies have shown that miRNA-21 and SNHG1 are generally overexpressed in cancer tissues versus compared with ANCTs, regardless of their tumor type or origin. [26] [27] [28] In the present study, we found that the level of miRNA-21 and SNHG1 in ESCC tissues is significantly higher than those in corresponding ANCTs. The high expression of miRNA-21 is positively correlated with advanced TNM stage and positive lymph node metastasis. Thus, our findings indicate that miRNA-21 can be a potential biomarker for ESCC. Further, the level of SNHG1 expression is found to be markedly related to lymph node metastasis and tumor size; which is consistent with the results of Zhang et al 28 Overall, these data suggest that miRNA-21 and SNHG1 are upregulated in ESCC tissues and correlate with lymph node metastasis, TNM stage, and tumor size. Traditional biomarkers used in the diagnosis of ESCC mainly include CEA, CA19-9, and SCCA. However, due to lack of high diagnostic sensitivity or specificity, the early diagnosis of ESCC still remains poor leading to early metastasis before diagnosis. Therefore, developing new diagnostic methods or new biomarkers for early diagnosis for ESCC is very essential. Nevertheless, the complex mechanisms of miRNA-21 and SNHG1 involved in cancer development are mostly tested in tissues. Thus, in order to apply this knowledge in clinical use; the critical influence of miRNA-21 and SNHG1 should be explored in most available diagnostic samples like blood and other body fluids. We have found that serum miRNA-21 and SNHG1 expression levels are higher in patients with ESCC than in healthy controls with an AUC value of ROC curves being determined to be 0.928 and 0.850, respectively. Consequently, the Pearson correlation coefficient indicated that the expression levels of miRNA-21 and SNHG1 in ESCC tissues are significantly associated with their respective serum expression levels; suggesting that circulating levels of miRNA-21 or SNHG1 may serve as suitable biomarkers for ESCC patients for initial clinical cancer diagnosis. Nevertheless, it has been reported that miRNA-21 of serum is upregulated in several types of cancers. [10] [11] [12] [13] These findings suggest that the upregulation of serum miRNA-21 is not specific to ESCC patients. Hence, the serum level of miRNA-21 alone cannot be a marker for early detection of ESCC, and multiple biomarkers are needed to achieve high specificity. Additionally, SNHG1 is a novel oncogenic lncRNA aberrantly expressed in different diseases including colorectal, liver, lung, prostate, gastric and ECs. 26 However, the sensitivity and specificity of SNHG1 still need to be further investigated. In conclusion, although the current studies indicate that high potential of miRNA-21 or SNHG1 to act as tumor biomarkers for ESCC diagnosis, more studies are necessary to identify novel biomarkers specific to ESCC for early detection. Next, the prognostic value of miRNA-21 and SNHG1 expression in ESCC patients is explored in this study. The upregulation of miRNA-21 and SNHG1 is found to be related to the reduction in OS and DFS, as shown by the Interactions between lncRNAs and miRNAs have been frequently observed during the development of human cancers, such as SNHG1 exacerbated HCC cell proliferation, migration, and invasion via the inhibition of miRNA-195 in vitro 31 In the present study, we further explored the interaction between miRNA-21 and SNHG1. Intriguingly, our in vitro data have revealed a novel regulatory pathway, in which miRNA-21 is likely an upstream positive regulator of SNHG1 in ESCC cells in a unidirectional manner. In addition, the interactions between miRNA-21 and SNHG1 aided the proliferation of ESCC cells. Therefore, our results indicate that SNHG1 may be a novel downstream target of miRNA-21 in ESCC cells and an important contributor towards proliferation abilities of ESCC cells. Yan et al 32 ceRNA regulatory SNHG11/miR-338-3p/CST3 axis decreases ESCC cell growth and induces apoptosis. However, the mechanism of this positive regulation between miRNA-21 and SNHG1 is yet unknown. However, our data suggest that SNHG1 may serve as a potential therapeutic target for ESCC by downregulating miRNA-21. Taken together, the present study has identified that miRNA-21 and SNHG1 are upregulated in ESCC tissues and serum. They are associated with lymph node metastasis, TNM stage, tumor size, and poor prognosis, and promote the proliferation of ESCC cells in vitro. SNHG1 may be a novel downstream target of miRNA-21 in ESCC cells in a unidirectional manner and critically contributes toward the proliferation potential of ESCC cells. Thus, miRNA-21 and SNHG1 may serve as potential diagnostic and prognostic biomarkers and therapeutic targets for ESCC.
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